We'll know at the September 2015 keynote event.
Aug 13, 2015 GLOVER JAMES T
10,000 Direct Purchase at $2.80 per share. 28,000
Aug 12, 2015 MURPHY KEITH
20,000 Direct Purchase at $2.56 per share. 51,200
Sentiment: Strong Buy
Then they have to go through Pivotal Trial Phase and Approval Phase. Translation = 5 - 7 years before possible FDA approval IMO. They have what 2 patients enrolled in the Pilot Phase? Seriously? It will take hundreds of patients before FDA approval IMO. Where's the money going to come from until then? Dilution IMO.
Actually ONVO will have millions in sales and revenues this year. It would be foolish to short ONVO at this level. The stock is clearly in an uptrend. You should go back to trading school.
Because the Scaffold is years and years away from FDA approval and it may never get FDA approval. Until FDA approval, there will no sales or revenues and more and more dilution just to pay for day to day operations. This was a penny stock for a reason. A reverse split won't change anything. It will sell off to sub $2 as the secondary offerings occur and they burn through cash with no sales or revenues for years. Short to mid term it's the perfect stock to short. Long term like 10 years plus it's a buy.
Nothing more than a manipulated penny stock trading on the OTC market.
I am not seeing what everyone is so excited about. Look at the fundamentals:
Price/Sales (ttm): 5.89
Price/Book (mrq): 8.97
Qtrly Revenue Growth (yoy): -6.80%
Qtrly Earnings Growth (yoy): -1.00%
Operating Cash Flow (ttm): -704.28K
Levered Free Cash Flow (ttm): -1.47M
I wouldn't be surprised if they disappoint again at earnings release and it goes back to $2.50 range. Sale of property will be a non event in my opinion.
In regards to MYDICAR, historically, these gene transfer techniques have not worked. Approximately 60 percent of all patients in the United States currently have AAV1 neutralizing antibodies to the SERCA2a enzyme. Also, they are only targeting systolic heart failure initially. The main potential in my opinion might be with the stem cell therapy. Celladon's stem cell therapy is only in the pre-clinical phase. I believe NeoStem has a better stem cell therapy. The company is developing AMR-001, an autologous adult stem cell product to treat damaged heart muscle following an acute myocardial infarction. It is currently in phase 2 of its PreSERVE clinical trial.
Because there are a lot of incredibly stupid people in this world that enjoy losing money.
Because MSLP has a much smaller float of 7.7 million shares vs. 45 million for MRIC. It's much easier to move MSLP with such a small float....supply and demand. With a float of 45 million MRIC needs institutional investors to move the stock which won't happen until it trades on a national exchange. Not to mention MSLP has a much better PR firm and is much better about attending investor conferences and spreading the work about their company and products...something MRIC really needs to work on.
By Dwight Einhorn
September 2, 2014 8:47 AM
In a report published Tuesday, MLV & Co. analyst George B. Zavoico reiterated a Hold rating and $5.00 price target on Cytokinetics (NASDAQ: CYTK).
In the report, MLV & Co noted, “Over the weekend, results of the international, randomized, double-blind Phase III PARADIGM-HF trial of LCZ696 versus enalapril in patients with chronic heart failure (CHF) were presented at the European Society of Cardiology (ESC) annual meeting in Barcelona, Spain. The trial was stopped early following an interim analysis by an independent Data and Safety and Monitoring Committee (DSMC) in March 2014 showing that LCZ696 demonstrated a statistically significant clinical benefit versus enalapril after a median follow-up of 27 months. If LCZ696 becomes the standard of care for patients with CHF, as some cardiologists now expect (based on comments at the ESC meeting), then we think it is likely that a combination of Cytokinetics' omecamtiv mecarbil with LCZ696 will have to be evaluated. Due to the different mechanisms of action we think omecamtiv may have an additive or synergistic effect with LCZ696, without sacrificing safety. We maintain our HOLD recommendation and $5.00 price target based on uncertainties regarding future development of tirasemtiv for the treatment of amyotrophic lateral sclerosis (ALS). We note that the PARADIGM-HF results do not change our positive outlook for omecamtiv.”
Cytokinetics closed on Friday at $4.28.